Nuviant Medical’s Neurostimulation System Selected by GlaxoSmithKline for Research in Bioelectronic Medicine


Liege, Belgium, Feb, 16, 2016 -- Nuviant Medical, Inc. ("Nuviant" or "the Company"), a developer and manufacturer of implantable neurostimulation systems, today announced that GlaxoSmithKline ("GSK") has selected Nuviant's proprietary neurostimulation system as a research platform for further exploration of the clinical applications of bioelectronic medicine. Under the partnership, Nuviant will supply GSK with implantable pulse generators and external devices for use in preclinical research.

Nuviant's Synapse™ neurostimulation system is the result of more than 15 years of development to create a flexible and versatile platform providing advanced clinical therapy and fundamental research capabilities for existing and future neuromodulation applications. Nuviant is currently using the device for clinical studies on deep brain stimulation as the company pursues US FDA approval. The Company also offers an iteration of the device to include a wireless, batteryless version that can be used for peripheral nerve stimulation.

"We look forward to working with GSK, a respected organization known for powerful innovation," says Nuviant President Hartmut Spitaels. "We are thrilled that they recognize the advanced capabilities of our device and are excited to partner with them via our development and manufacturing as we work towards the enhancement of bioelectronics."

About Nuviant Medical, Inc.

Nuviant is developing implantable neurostimulation systems for the relief of various chronic diseases and disorders. Nuviant's first product, the Synapse™ system, has received the CE Mark for certain movement disorders. Nuviant intends to use the product in additional human clinical studies and to prepare it for commercialization in select world markets. Nuviant has produced and tested its device in accordance with FDA Good Manufacturing Practices in its 10,000-square-foot, state-of-the-art cleanroom.  For more information, please visit the Nuviant website at

About Bioelectronics at GSK

GSK, one of the world's leading research-based pharmaceutical and healthcare companies, is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturized, implantable devices. The devices would be designed to interface with peripheral nerves to modulate specific organs with intent to treat a range of chronic diseases. For more information, please visit the GSK website at

Forward-Looking Statements: This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.